Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy

Details

Files

Project Status:

Complete

Project Line:

Health Technology Review

Project Sub Line:

Technology Review

Project Number:

HC0063-000

Inflammatory bowel disease, a chronic gastrointestinal condition that includes Crohn disease and ulcerative colitis, is managed with various drug classes, which include targeted immune modulators such as biologics and small molecule drugs. Due to the substantial expenditures in Canada on biologic drugs and the evolving dynamics related to loss of exclusivity, the introduction of new drugs, biosimilars, and generics, as well as the availability of new evidence, there will be increasing questions regarding the appropriate sequencing of these advanced therapies. This utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.

Files

Final Report View PDF

Last Updated : July 11, 2024